Compare the effects of different visfatin concentration on cardiovascular risk factors, adiponectin and insulin resistance in patients with T2DM

Caro, 2002, Lifetime costs of complications resulting from type 2 diabetes in the U.S., Diabetes Care, 25, 476, 10.2337/diacare.25.3.476

Pyorala, 1987, Diabetes and atherosclerosis: an epidemiologic view, Diabetes Metab Rev, 3, 463, 10.1002/dmr.5610030206

de Vegt, 1999, Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn study, Diabetologia, 42, 926, 10.1007/s001250051249

Kannel, 1979, Diabetes and cardiovascular risk factors: the Framingham study, Circulation, 59, 8, 10.1161/01.CIR.59.1.8

Wingard, 1995, Heart disease and diabetes, vol. 95, no. 1468

Bloomgarden, 2002, Adiposity and diabetes, Diabetes Care, 25, 2342, 10.2337/diacare.25.12.2342

Khan, 2006, Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents, Nat Struct Mol Biol, 13, 582, 10.1038/nsmb1105

Arner, 2005, Insulin resistance in type 2 diabetes—role of the adipokines, Curr Mol Med, 5, 333, 10.2174/1566524053766022

Frayn, 2000, Subcutaneous and visceral adipose tissue their relation to metabolic syndrome, Endocr Rev, 21, 697, 10.1210/er.21.6.697

Chen, 2006, Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes, J Clin Endocrinol Metab, 91, 295, 10.1210/jc.2005-1475

Pagano, 2006, Reduced plasma visfatin/pre B-cell colony enhancing factor in obesity is not related to insulin resistance in humans, J Clin Endocrinol Metab, 91, 3165, 10.1210/jc.2006-0361

Berndt, 2005, Plasma visfatin concentrations and fat depot-specific mRNA expression in humans, Diabetes, 54, 2911, 10.2337/diabetes.54.10.2911

Kasahara, 1993, A new redox-cofactor vitamin for mammals, Nature, 422, 832, 10.1038/422832a

Alberti, 1998, Definition, diagnosis and classification of diabetes mellitus and its complications. Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation, Diabet Med, 15, 539, 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S

Matsuzawa, 2006, Therapy insight: adipokines in metabolic syndrome and related cardiovascular disease, Nat Clin Pract Cardiovasc Med, 3, 35, 10.1038/ncpcardio0380

Sun, 2007, Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men, Am J Clin Nutr, 85, 399, 10.1093/ajcn/85.2.399

Dogru, 2007, Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired tolerance, Diabetes Res Clin Pract, 76, 24, 10.1016/j.diabres.2006.07.031

Kralisch, 2005, Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes, J. Endocrinol, 185, R1, 10.1677/joe.1.06211

Kralisch, 2005, Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes, Am J Physiol Endocrinol Metab, 289, E586, 10.1152/ajpendo.00090.2005

Blaak, 2001, Gender differences in fat metabolism, Curr Opin Clin Nutr Metab Care, 4, 499, 10.1097/00075197-200111000-00006

MacLaren, 2007, Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre adipocytes and adipocytes, Diabetes Obes Metab, 9, 490, 10.1111/j.1463-1326.2006.00625.x

Sandeep, 2007, Serum visfatin in relation to visceral fat, obesity and type 2 diabetes mellitus in Asian Indians, Metab Clin Exp, 56, 565, 10.1016/j.metabol.2006.12.005

Wang, 2007, The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile, Eur J Physiol, 454, 971, 10.1007/s00424-007-0262-y

Samara, 2008, Visfatin, low-grade inflammation and body mass index (BMI), Clin Endocrinol, 69, 568, 10.1111/j.1365-2265.2008.03205.x

Takebayashi, 2007, Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus, Metab Clin Exp, 56, 451, 10.1016/j.metabol.2006.12.001